HuGE Literature Finder
Records
1
-
30
| Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. Journal of cancer research and clinical oncology 2022 Jul . Li Peng, Che Shuyu, Qi Yingxue, Luo Ningning, Lin Qiuju, Zhu Xiaofeng, Xuan Yunpeng, Li Mengmeng, Li Jinlong, Ge Minghui, Sun Tingting, Qi Chuang, Wang Yongj |
| Association between epidermal growth factor receptor gene mutation status and short-term efficacy of first-line platinum-containing chemotherapy in advanced non-small cell lung cancer. Biomedical reports 2022 Jul 17 (1): 56. Chen Lin, Qi Qiufeng, Zhu Ming, Zhang Yaping, Peng Yun, Liu Yongpi |
| Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands) 2022 Jul 170 176-184. Ahn Bokyung, Yoon Shinkyo, Kim Deokhoon, Chun Sung-Min, Lee Goeun, Kim Hyeong-Ryul, Jin Jang Se, Sang Hwang H |
| Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2022 Jul . Deng Rui, Liu Jinkun, Song Tongjun, Xu Tao, Li Yong, Duo Long, Xiang Longchao, Yu Xiongjie, Lei Jinhua, Cao Fengj |
| Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer. BMC cancer 2022 Jul 22 (1): 775. Matsumoto Yoshiya, Kawaguchi Tomoya, Watanabe Masaru, Isa Shun-Ichi, Ando Masahiko, Tamiya Akihiro, Kubo Akihito, Kitagawa Chiyoe, Yoshimoto Naoki, Koh Yasuhi |
| Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients. Cancer chemotherapy and pharmacology 2022 Jul . Kenmotsu Hirotsugu, Imamura Chiyo K, Kawamura Takahisa, Oyakawa Takuya, Omori Shota, Nakashima Kazuhisa, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Yamamoto Nobuyuki, Takahashi Toshiaki, Tanigawara Yusu |
| RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. Cancer chemotherapy and pharmacology 2022 Jul . Nakagawa Kazuhiko, Garon Edward B, Gao Ling, Callies Sophie, Zimmermann Annamaria, Walgren Richard, Visseren-Grul Carla, Reck Mart |
| A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. BMC medical genomics 2022 Jun 15 (1): 141. Chen Yan, Jiang Bo, He Yuange, Zhang Chu, Zhou Wenjie, Fang Cheng, Gu Dejian, Zhang Minxia, Ji Mei, Shi Juntao, Yang X |
| Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Jun . Piccirillo Maria Carmela, Bonanno Laura, Garassino Marina Chiara, Esposito Giovanna, Dazzi Claudio, Cavanna Luigi, Burgio Marco Angelo, Rosetti Francesco, Rizzato Simona, Morgillo Floriana, Cinieri Saverio, Veccia Antonello, Papi Maximilan, Tonini Giuseppe, Gebbia Vittorio, Ricciardi Serena, Pozzessere Daniele, Ferro Alessandra, Proto Claudia, Costanzo Raffaele, D'Arcangelo Manolo, Proietto Manuela, Gargiulo Piera, Di Liello Raimondo, Arenare Laura, De Marinis Filippo, Crinò Lucio, Ciardiello Fortunato, Normanno Nicola, Gallo Ciro, Perrone Francesco, Gridelli Cesare, Morabito Alessand |
| Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA network open 2022 Jun 5 (6): e2215589. Liu Yufei, Zhang Zhe, Rinsurongkawong Waree, Gay Carl M, Le Xiuning, Ning Matthew S, Lewis Jeff, Rinsurongkawong Vadeerat, Lee J Jack, Roth Jack, Swisher Stephen, Gandhi Saumil, Lee Percy P, Gibbons Don L, Vaporciyan Ara A, Heymach John V, Zhang Jianjun, Lin Steven |
| Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer medicine 2022 Jun . Ehrenstein Vera, Eriksen Katrine, Taylor Aliki, Servidio Leslie, Jakobsen Er |
| Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC cancer 2022 Jun 22 (1): 654. Gen Soei, Tanaka Ichidai, Morise Masahiro, Koyama Junji, Kodama Yuta, Matsui Akira, Miyazawa Ayako, Hase Tetsunari, Hibino Yoshitaka, Yokoyama Toshihiko, Kimura Tomoki, Yoshida Norio, Sato Mitsuo, Hashimoto Naozu |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Jun . Lu Shun, Zhang Yiping, Zhang Guojun, Zhou Jianying, Cang Shundong, Cheng Ying, Wu Gang, Cao Peiguo, Lv Dongqing, Jian Hong, Chen Chengshui, Jin Xiangming, Tian Panwen, Wang Kai, Jiang Guanming, Chen Gongyan, Chen Qun, Zhao Hui, Ding Cuimin, Guo Renhua, Sun Guoping, Wang Bin, Jiang Liyan, Liu Zhe, Fang Jian, Yang Junquan, Zhuang Wu, Liu Yunpeng, Zhang Jian, Pan Yueyin, Chen Jun, Yu Qitao, Zhao Min, Cui Jiuwei, Li Dianming, Yi Tienan, Yu Zhuang, Yang Yan, Zhang Yan, Zhi Xiuyi, Huang Yunchao, Wu Rong, Chen Liangan, Zang Aimin, Cao Lejie, Li Qingshan, Li Xiaoling, Song Yong, Wang Donglin, Zhang Shucai, Ding Lieming, Zhang Ling, Yuan Xiaobin, Yao Lin, Shen Zhil |
| Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. Thoracic cancer 2022 Jun . Hosomi Yukio, Seto Takashi, Nishio Makoto, Goto Koichi, Yamamoto Noboru, Okamoto Isamu, Tajima Kosei, Kajihara Yusuke, Yamamoto Nobuyu |
| Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. The Lancet. Respiratory medicine 2022 Jun . Shi Yuankai, Chen Gongyan, Wang Xiang, Liu Yunpeng, Wu Lin, Hao Yanrong, Liu Chunling, Zhu Shuyang, Zhang Xiaodong, Li Yuping, Liu Jiwei, Cao Lejie, Cheng Ying, Zhao Hui, Zhang Shucai, Zang Aimin, Cui Jiuwei, Feng Jian, Yang Nong, Liu Fei, Jiang Yong, Gu Chuan, |
| Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. Journal of clinical medicine 2022 Jun 11 (12): . Lee Tai-Huang, Chen Hsiao-Ling, Chang Hsiu-Mei, Wu Chiou-Mei, Wu Kuan-Li, Kuo Chia-Yu, Wei Po-Ju, Chen Chin-Ling, Liu Hui-Lin, Hung Jen-Yu, Yang Chih-Jen, Chong Inn-W |
| Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open 2022 Jun 7 (3): 100507. Dafni U, Soo R A, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J-Y, De Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R |
| Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients. Cancer medicine 2022 Jun . Tian Hong-Xia, Chen Zhi-Hong, Jie Guang-Ling, Wang Zhen, Yan Hong-Hong, Wu Si-Pei, Zhang Shui-Lian, Lu Dan-Xia, Zhang Xu-Chao, Wu Yi-Lo |
| Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study. Cancer medicine 2022 Jun . Hu Chunhong, Wu Sixuan, Deng Renfang, Wu Yuanqiang, Pan Yue, Shu Long, Wu Fa |
| Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). International journal of clinical oncology 2022 Jun . Haratake Naoki, Shimokawa Mototsugu, Seto Takashi, Yoshioka Hiroshige, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Mitsudomi Tetsu |
| Cytoplasmic expression of G protein-coupled estrogen receptor 1 correlates with poor postoperative prognosis in non-small cell lung cancer. Journal of thoracic disease 2022 May 14 (5): 1466-1477. Li Zhen-Hua, Liu Chang, Liu Qing-Hua, Wang Jian, Wang Ying, Wang Yan-Fei, Deng Shou-Jun, Li Ding-Bi |
| The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. Translational lung cancer research 2022 May 11 (5): 776-785. Zhao Yizhuo, Wang Qiming, Zhang Li, Shi Jianhua, Wang Zhehai, Cheng Ying, He Jianxing, Shi Yuankai, Chen Weiqiang, Luo Yi, Wu Lin, Wang Xiuwen, Nan Kejun, Jin Faguang, Dong Jian, Li Baolan, Yamaguchi Fumihiro, Breadner Daniel, Nagano Tatsuya, Tanaka Fumihiro, Husain Hatim, Li Kai, Han Baoh |
| Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC. Emergency medicine international 2022 2022 3112281. Qiao Man, Li Dongsheng, He Yuan, Zhang Cen, Chi Hang, Li Xiaoqiu, Cui QingMing, Li ShaoYing, Jiao Ying, Wei Yu |
| Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. Frontiers in oncology 2022 12 863666. Yi Xiao-Fang, Song Jun, Gao Ruo-Lin, Sun Li, Wu Zhi-Xuan, Zhang Shu-Ling, Huang Le-Tian, Ma Jie-Tao, Han Cheng- |
| Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD). International journal of chronic obstructive pulmonary disease 2022 17 1601-1612. Ma Hongxia, Zhang Qian, Zhao Yanwen, Zhang Yaohui, Zhang Jingjing, Chen Guoqing, Tan Yuan, Zhang Qin, Duan Qianqian, Sun Tingting, Qi Chuang, Li Fengs |
| Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways. American journal of cancer research 2022 12 (6): 2576-2593. Lai Yihua, Chang Hsiuhui, Chen Hueiwen, Chang Geechen, Chen Jeremy |
| Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer. The Korean journal of internal medicine 2022 07 37 (4): 811-820. Jang Seung Hun, Lee Dong Yoon, Jeong Jihyeon, Choi Won- |
| A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution. Lung India : official organ of Indian Chest Society 0 39 (4): 315-318. Roy Mohana, Bal Amanjit, Gupta Nalini, Prasad Kuruswamy T, Wakelee Heather A, Singh Navne |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 09, 2022
- Content source: